deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02859064

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)

Sponsor: Ipsen

Conditions Carcinoid Tumors Gastrointestinal Neoplasms Neuroendocrine Tumors
Interventions Lanreotide Y-90 microspheres
Updated 21 times since 2017 Last updated: Dec 1, 2023 Started: Jul 28, 2017 Primary completion: May 27, 2022 Completion: Jun 10, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Closed due to slow accrual

Other terminated trials from Ipsen

See all terminations from Ipsen

A PHASE2 clinical study on Carcinoid Tumors and Gastrointestinal Neoplasms, this trial is terminated or withdrawn. The trial is conducted by Ipsen and has accumulated 21 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~May 2018 · 5 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Aug 2020 · 14 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~May 2021 · 3 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~May 2022 · 5 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2024 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Aug 2023 — Jan 2024 [monthly]

    Terminated PHASE2

  5. Sep 2022 — Aug 2023 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

▶ Show 16 earlier versions

  1. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  2. May 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  5. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Feb 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  10. Jun 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  11. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  12. Dec 2017 — May 2018 [monthly]

    Recruiting PHASE2

  13. Jun 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  14. Mar 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Feb 2017 — Mar 2017 [monthly]

    Not Yet Recruiting PHASE2

  16. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ipsen
  • SCRI Development Innovations, LLC
Data source: SCRI Development Innovations, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations